The type I insulin-like growth factor receptor (IGF-IR) plays an important role in the growth and transformation of breast cancer cells. In this study, we investigated the effects of treatment with an antisense IGF-IR construct on cells from the highly metastatic estrogen receptor-negative human breast cancer cell line MDA-MB-435s. The cells carrying the antisense IGF-IR had a markedly reduced expression of IGF-IR, had a significant decrease in cell proliferation, and lost the ability to form colonies in soft agar. There was a delay in tumor formation and a dramatic reduction in tumor size when cells carrying the antisense IGF-IR were injected into either nude or severe combined immunodeficient (scid) beige mice. We have also provided data that show that the scid beige mouse is a more suitable model for studying metastasis of the MDA-MB-435s cells. All of the scid beige mice injected with cells carrying the control construct had metastasis to the lungs, whereas lungs from the nude mice had no apparent metastatic sites after 11 weeks. When cells carrying antisense IGF-IR were injected subcutaneously in scid beige mice, the animals had a significant increase in survival compared with mice injected with cells carrying the control construct. Taken together, these results indicate that the IGF-IR can play a critical role in the progression of breast cancer. Our studies provide a basis for the development of future treatment strategies targeting the IGF-IR in metastatic breast cancer. Cancer Gene Therapy (2000) 7, 384 -395
B
reast cancer kills ϳ50,000 women each year in North America, and world figures are ϳ10-fold higher. 1 The incidence of breast cancer has been steadily increasing, while the mortality rates for breast cancer have not changed significantly for the last 50 years. 2 A major characteristic of tumor malignancy and the primary cause of mortality in patients with breast cancer is the ability of the tumor cells to metastasize to distant sites. Breast cancer mortality is related to the capacity of the tumor cell to invade, metastasize, and proliferate. 3 Later stages of breast cancer involve metastasis to bone, brain, and other organs where conventional treatments are often no longer effective. Therefore, it is important to define the role of the genes that are responsible for the progression of breast cancer cells to the metastatic phenotype and to develop treatment strategies that target these genes.
The type I insulin-like growth factor receptor (IGF-IR) has been shown to play a central role in the mechanism of malignant transformation. 4 Chemical cross-linking studies carried out on several breast cancer cell lines demonstrated that the cells have the IGF-IR. 5 Furthermore, breast tumor specimens and breast cancer epithelial cell lines have been shown to express mRNA encoding IGF-IR. 6 Several studies have reported that IGF-IR levels are significantly higher in breast cancer tissue compared with normal breast tissue or benign tumors. [7] [8] [9] Patients with tumors containing a high IGF-IR gene copy number tend to have a shorter median overall survival than patients with tumors having a low amplified IGF-IR gene copy number. 10 Indeed, a recent study has shown that IGF-IR expression was 14-fold higher and that IGF-IR autophosphorylation and kinase activity were 2-to 4-fold higher in malignant breast tissue than in normal breast tissue. 11 This amounts to a 40-fold elevation in IGF-IR tyrosine kinase activity in malignant breast tissue.
Studies from several laboratories including our own have used antisense strategies that target IGF-IR to show inhibition of tumor growth for melanoma, 12 glioblastoma, 13 human lung cancer cells, 14 rhabdomyosarcoma, 15 osteosarcoma, 16 mesothelioma, 17 and prostate cancer. 18, 19 In addition, a recent study by our group has shown that inhibition of IGF-IR expression in rat glio-blastoma cells can be brought about using a triple helix strategy. 20 It has also been reported that MCF-7 human breast cancer cells transfected with a construct carrying antisense for IGF-IR RNA displayed a reduced growth rate in culture conditions. 21 Furthermore, it has been demonstrated previously that the use of ␣IR3, an antibody specific for IGF-IR, inhibited cell proliferation and suppressed the tumor growth of MDA-MB-231 human breast cancer cells. 22 However, a recent study has shown that overexpression of the IGF-IR promotes aggregation, growth, and cell survival in MCF-7 human breast cancer cells. 23 Therefore, our hypothesis was that IGF-IR played a role in human metastatic breast cancer, and that cancer cells treated with a stable antisense IGF-IR-expressing construct have a decreased probability of forming metastases.
In this study, we have applied an antisense strategy targeting the IGF-IR to a metastatic estrogen receptornegative human breast cancer cell line, MDA-MB-435s.
We provide data that demonstrate the efficacy of this approach for inhibiting the growth of these highly metastatic human breast cancer cells in vitro as well as in vivo. We have also shown the importance of establishing and using the optimal animal model for assessing tumor growth and the metastatic potential of cells in vivo. Moreover, we have observed that transfection of MDA-MB-435s human breast cancer cells with an antisense IGF-IR construct can significantly inhibit the incidence of lung metastases and prolong survival when these cells are injected into animals.
MATERIALS AND METHODS

Cell lines and cell culture
MDA-MB-435s human breast cancer cells were purchased from the American Type Culture Collection (Manassas, Va). These human breast cancer cells, which were derived from the parent MDA-MB-435 cell line, were used in this study because they display a highly metastatic phenotype. 24 The parent cell line originated from a pleural effusion in a 31-year-old female with metastatic, ductal adenocarcinoma of the breast. No systemic therapy was given to the patient before establishing the cell line. The cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (Life Technologies, Gaithersburg, Md) supplemented with 10% fetal bovine sera (FBS) (HyClone Laboratories, Logan, Utah). Culture medium for transfected MDA-MB-435s cells was supplemented with geneticin at 500 g/mL (Life Technologies) to maintain selection pressure. All of the experiments were carried out using cells from early passages (P 2 or P 3 ). Before injection into 4-to 6-week-old female athymic nude or severe combined immunodeficient (scid) beige mice, cells (2 ϫ 10 6 ) were washed once in phosphate-buffered saline (PBS), treated with Versene 1:5000 (Life Technologies) for 3-5 minutes, and resuspended in PBS.
Construction of vectors
To assemble the pRcII/cytomegalovirus (CMV) vector used in these experiments, a pRc/CMV vector (Invitrogen, Carlsbad, Calif) was modified by removing DNA sequences from nucleotide position 995 (ApaI site in the multiple cloning site) to nucleotide position 2100 (SmaI site upstream of the neomycin resistance gene). Resulting DNA fragments were separated by agarose gel electrophoresis. A 4.3-kb vector fragment was isolated with a United States Bioclean kit (United States Biochemical, Cleveland, Ohio) and religated with T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind). After transformation, the modified vector pRcII/CMV was grown in Escherichia coli and subsequently purified with a plasmid isolation kit (Qiagen, Chatsworth, Calif). The human IGF-IR cDNA 697-bp fragment (nucleotide position 42 in exon 1 to nucleotide position 738 in exon 3, GenBank accession no. M24599) that was obtained from total RNA isolated from T47D human breast cancer cells by reverse transcriptase polymerase chain reaction (described in Burfeind et al 19 ) was cloned into the HindIII/EcoRI sites of the pRcII/CMV vector in the antisense orientation (Fig 1A) . To assemble the sense vector, the 697-bp IGF-IR cDNA fragment was cloned into the EcoRI/PstI sites of the plasmid pBluescript II SK (Stratagene, La Jolla, Calif), which was then cloned into the HindIII/NotI sites of the pRcII/CMV vector (Fig 1B) . The directional Schematic representation of the  antisense IGF-IR vector (IGF-IRAS) and the  sense IGF-IR (IGF-IRS) cloning of the sense and antisense IGF-IR cDNA inserts was confirmed by restriction mapping.
Transfection
MDA-MB-435s human breast cancer cells were transfected with the antisense IGF-IR vector, with the sense IGF-IR vector, or with the pRcII/CMV control vector using Lipofectin (Life Technologies) according to the supplier's instructions. Geneticin (G418 sulfate) (Life Technologies) at a concentration of 1 mg/mL was used to select for cells that were neomycin-resistant, indicating that the vector was present in the cells. Several (n ϭ 11) individual cell clones were isolated from the population of cells carrying the antisense IGF-IR vector. All of the transfected cells and cell clones were maintained in DMEM with 10% FBS and G418 (0.5 mg/mL).
Northern blot analysis
Total RNA was isolated from cells with Trizol reagent (Life Technologies). Poly(A ϩ ) RNA was then selected using the Messagemaker reagent assembly (Life Technologies) according to the manufacturer's instructions. Samples (5 g of poly(A ϩ ) RNA or 20 g of total RNA) were electrophoresed on a 1% denaturing agarose gel followed by transfer to a Hybond-N nylon membrane (Amersham Lifesciences, Arlington Heights, Ill). The cDNA probes, a 0.7-kb fragment from the human IGF-IR sequence, and a 2.2-kb fragment of chicken ␤-actin were labeled with [␣-32 P]deoxycytidine triphosphate (DuPont New England Nuclear Research Products, Boston MA) using the random hexanucleotide primer method. 25 Northern blot hybridization was carried out in 5ϫ standard saline citrate (SSC), 5ϫ Denhardt's solution, 10% (wt/vol) dextran sulfate, 0.1% (wt/vol) sodium dodecyl sulfate (SDS), and 100 g/mL denatured salmon sperm DNA at 65°C for 18 hours. After hybridization, the membrane was washed for 15 minutes at room temperature with 2ϫ SSC followed by a final 15-minute wash in a solution consisting of 0.5ϫ SSC and 0.5% SDS (wt/vol) at 65°C. The membranes were exposed to x-ray film for 6 -12 hours at Ϫ80°C. X-ray films were analyzed with a SciScan 5000 laser densitometer (United States Biochemical) and normalized relative to ␤-actin mRNA.
Proliferation assays
The tetrazolium salt (3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyltetrazolium bromide (MTT)) method involving conversion of MTT to colored formazan by cells serves an as indirect measurement of cell growth and is an accurate reproducible means of measuring cell viability. 26 Therefore, a modified MTT assay was used to determine cell proliferation rates in MDA-MB-435s human breast cancer cells from clones C8 and C9 carrying antisense IGF-IR, cells transfected with sense IGF-IR, or cells transfected with the control vector. Cells were seeded into each well (2.5 ϫ 10 3 cells/well) of 96-well plates. MTT (20 L, 5 mg/mL in PBS) (Sigma, St. Louis, Mo) was added on day 0, day 1, day 3, or day 5 of culture. The reaction was stopped after 1 hour of incubation at 37°C by addition of 100 L of solubilization buffer (20%SDS (wt/vol) in 50% dimethylformamide; pH 5). Plates were then incubated at 37°C for 4 -16 hours. An enzyme-linked immunosorbent assay reader (Dynatech MR 5000; Dynatech Laboratories, Chantilly, Va) was used to measure absorbance at a wavelength of 570 nm and a reference wavelength of 690 nm. The reported cell numbers were extrapolated from a standard curve generated for each cell line and experiment relating absorbance to a known cell number. Data points are represented as the mean Ϯ SE of six wells. All assays were repeated several times.
Soft agar colony-forming assay
For soft agar assays, a bottom layer of 1 mL of the corresponding culture media containing 0.6% agar (Difco Laboratories, Detroit, Mich) and 10% FBS was prepared, placed in 35-mm culture dishes (Corning Glass Works, Corning, NY), and allowed to solidify. Cells (2.5 ϫ 10
3 ) from the C8 and C9 clones carrying antisense IGF-IR, cells carrying sense IGF-IR, or cells transfected with the vector minus the inserts were suspended in 50 L of DMEM containing 10% FBS and 0.5 mg/mL G418. Culture medium (1 mL) containing 0.3% agarose (Boehringer Mannheim) was added to the cell suspension before seeding on the dishes. Triplicates were performed for each type of cell. Cells were incubated at 37°C in 5% CO 2 atmosphere. Dishes were examined twice per week, and colonies were counted manually after 4 weeks. Results are expressed as mean Ϯ SE.
DNA fragmentation assay for apoptosis
Cells (1 ϫ 10 6 ) from MDA-MB-435s clones C8 and C9 as well as cells that were transfected with the control vector were seeded in 15 mL of DMEM containing 10% FBS and 0.5 mg/mL G418. On day 3 of culture, the medium was replaced with serum-free DMEM. The cells were then maintained in serum-free media for 3 or 5 days. Nonadherent cells and adherent cells treated with trypsin were combined. Genomic DNA was isolated from the combined cells using a Promega Genomic DNA isolation kit (Promega, Madison, Wis) according to the manufacturer's protocol. Genomic DNA (4 g) and the molecular weight marker DNA/EcoRI ϩ HindIII (Boehringer Mannheim) (0.25 g) were radiolabeled by Taq polymerase. 27 To label with Taq polymerase, the DNA was added to 20 L of labeling mixture with a final concentration of 10 mM tris(hydroxymethyl)aminomethane-HCl (pH 9.0), 50 mM KCl, 0.1% Triton X-100, 10 mM MgCl 2 , 2 Ci [␣-
32 P]deoxyadenosine triphosphate (3000 Ci/mmol), and 1 U Taq polymerase. Reactions were incubated at 72°C for 20 minutes and terminated by the addition of gel loading buffer. The labeled DNA was electrophoresed on a 1.5% agarose gel. The gel was then exposed to x-ray film for 5 minutes at room temperature to visualize the bands.
Terminal deoxynucleotidyltransferase-mediated uridine triphosphate nick-end labeling (TUNEL) analysis
Cells (1 ϫ 10 6 ) from the MDA-MB-435s C9 clone and cells transfected with the control vector were seeded in 15 mL of DMEM containing 10% FBS and 0.5 mg/mL G418 in T-75 flasks (Corning Glassworks, Corning, NY). On day 3 of culture, the medium was replaced with serum-free DMEM. Cells were harvested on the day 5 of serum withdrawal. Adherent cells were trypsinized and combined with nonadherent cells. The cells were then washed and adjusted to 1-2 ϫ 10 7 cells/mL with PBS. A volume of 100 L of the cell suspension was taken from each sample, and 100 L of freshly prepared paraformaldehyde solution (4% in PBS, pH 7.4) was added to the cell suspension. Samples were incubated for 30 minutes at room temperature on a shaker followed by centrifugation at 300 ϫ g for 10 minutes. The fixative was removed, and the cells were washed with 200 L of PBS and centrifuged at 300 ϫ g for 10 minutes. Cells were then resuspended in 100 L of permeabilization solution (0.1% Triton X-100 in 0.1% sodium citrate) for 4 minutes at room temperature. After permeabilization, cells were washed two times in PBS (200 L) and further processed using a fluorescein in situ cell death detection kit (Boehringer Mannheim). Briefly, the cells were resuspended in 50 L of TUNEL reaction mixture and incubated for 60 minutes at 37°C in the dark. The samples were washed two times in PBS (200 L/wash), and the cells were transferred to a tube (Falcon 2063) to a final volume of 250 L in PBS. The negative control was carried out in a similar manner using the label solution (without terminal transferase) in place of TUNEL reaction mixture. For the positive control, cells were treated with deoxyribonuclease I (10 U/mL, 10 minutes at 37°C) to induce DNA strand breaks before labeling with TUNEL solution. The samples were analyzed by flow cytometry using an Elite ESP (Coulter, Miami, Fla). Excitation was at 488 nm with emission read in the BP 525/25. Data were acquired using logarithmic amplification of the fluorescein isothiocyanate signal. Data were analyzed using Elite Acquisition software (Coulter).
Assay of tumor growth and metastases in animal models
Female BALB/c nude mice (4 -6 weeks of age) and scid beige mice (4 -6 weeks of age) were used. Nude mice were bred and maintained in the athymic animal facility at Case Western Reserve University School of Medicine. Scid beige mice were purchased from Charles River Laboratories (Wilmington, Mass) and maintained in the athymic animal facility at Case Western Reserve University. The MDA-MB-435s human breast cancer cells from clones C8 and C9 carrying the antisense IGF-IR construct or the control cells carrying the construct minus the antisense IGF-IR insert were injected through a 22-gauge needle over the right scapula of the mice. All cells were injected in a volume of 100 L at a concentration of 2 ϫ 10 6 viable cells. The tumor take rate when the control cells were injected in the scapular region was 100%. Tumors were measured every week with vernier calipers. Tumor volume was calculated according to the following formula: volume ϭ (width) 2 ϫ length/2. Animals were sacrificed after 11 weeks, and tumors were excised and weighed. The lungs were removed, rinsed in PBS, and placed in Bouin's solution for 24 hours before counting the number of metastatic sites. For the survival curve, animals were sacrificed when the tumor size was Ͼ10% of the animal's weight or when the tumor ulcerated.
RESULTS
The aim of the series of experiments carried out in this study was to assess the effect of treatment by an antisense IGF-IR gene targeting approach on cells from the estrogen receptor-negative human breast cancer cell line MDA-MB-435s. The objectives were to evaluate the role of IGF-IR in cell growth, tumorigenesis, and metastases in this highly metastatic human breast cancer cell line.
After transfection of the MDA-MB-435s human breast cancer cells with a vector containing the IGF-IR cDNA in an antisense direction, several clones carrying the antisense IGF-IR construct were identified and maintained in culture. In addition, MDA-MB-435s cell populations carrying the sense construct or the control vector (construct minus the IGF-IR inserts) were identified. Northern blot analysis was carried out on all of the clones to select the cell populations that displayed the highest level of expression of antisense IGF-IR (data not shown). The two clones, C8 and C9, that showed the highest levels of antisense IGF-IR expression coupled with the greatest suppression of endogenous IGF-IR expression were used to further assess the role of IGF-IR in cell growth, tumor formation, and metastases.
The two MDA-MB-435s human breast cancer cell clones, C8 and C9, showed strong expression of antisense IGF-IR by Northern blot analysis of poly(A ϩ ) RNA (Fig 2A, lanes 2 and 3) . The level of expression for the 11-kb principal transcript for IGF-IR was significantly decreased in cells from the C8 and C9 clones (Fig  2A, lanes 2 and 3) compared with the level of IGF-IR expression by the control transfected cells (Fig 2A, lane 1). Densitometric evaluation of the Northern blots indicated that expression of endogenous IGF-IR was reduced by 43% in cells from the C8 clone (Fig 2C, u) and by 56% in cells from the C9 clone (Fig 2C, Ⅺ) relative to the level of expression of IGF-IR in cells transfected with the control vector (Fig 2C, f) . The filter was rehybridized with a cDNA probe for chicken ␤-actin to verify the integrity and amount of poly(A ϩ ) RNA in the samples (Fig 2B) .
A series of assays were performed to characterize the proliferative effects after treatment of MDA-MB-435s cells with the antisense IGF-IR construct. The proliferation rate of the cells from the C8 (Fig 3A, OE) and C9 (Fig 3A, F) clones carrying the antisense IGF-IR construct was significantly inhibited on days 3 and 5 when compared with the proliferation rate of control cells carrying the construct minus the IGF-IR inserts (Fig 3A,  F) . To determine whether the inhibition was specific for the MDA-MB-435s cells transfected with the antisense IGF-IR construct, an additional assay was carried out with MDA-MB-435s cells transfected with the sense IGF-IR construct. Cells carrying sense IGF-IR (Fig 3B,  f) showed a proliferation rate similar to that of cells transfected with the control vector (Fig 3B, ࡗ) , whereas cells from the C9 clone (Fig 3B, F) carrying the antisense IGF-IR construct had a markedly decreased cell proliferation rate on days 3 and 5. In addition to slower growth rates, significant numbers of nonadherent cells were present in cultures of the C8 and C9 cell clones carrying the IGF-IR antisense construct compared with the control transfected cells or cells carrying the sense IGF-IR construct (data not shown). Anchorage-independent growth in the semisolid medium of soft agar is a strong indicator of the transformed phenotype and a more stringent test of mitogenic capacity because several cycles of cell division are required to form detectable colonies. Therefore, a series of soft agar assays was performed to assess the ability of human breast cancer cells treated with antisense IGF-IR to form colonies in soft agar. Colony formation in soft agar was completely abrogated in cells from the C8 and C9 clones carrying the antisense IGF-IR construct (Fig 4A  and 4B, respectively) . However, cells carrying the sense IGF-IR (Fig 4C) or the construct minus the inserts ( Fig  4D) exhibited avid clonogenic growth under identical culture conditions. There was no apparent colony formation from cells carrying the antisense IGF-IR construct, whereas the cells transfected with the control vector or the sense construct displayed avid colony formation after 28 days in culture (Table 1) .
A decrease in the number of IGF-IRs by treatment with an antisense approach has been shown to trigger massive apoptosis (programmed cell death) in several types of cancer cells. 28 Therefore, two independent methods were used to determine whether MDA-MB435s human breast cancer cells carrying antisense IGF-IR were apoptotic: a DNA fragmentation laddering assay and fluorescence-activated cell sorter analysis. In the first set of experiments, a DNA fragmentation assay was performed using cells from the C8 and C9 clones carrying antisense IGF-IR as well as cells transfected with the control vector. The characteristic ladder that forms when genomic DNA is electrophoresed on standard agarose gels shows that cells are undergoing apoptosis. Figure 5 shows a DNA ladder analysis carried out on the C8 and C9 clones carrying antisense IGF-IR. Cells from the C8 and C9 clones exhibited DNA laddering on day 3 of serum withdrawal (Fig 5, lanes 3 and 5, respectively), with more prominent laddering occurring on day 5 of serum withdrawal (Fig 5, lanes 4 and 6,  respectively) . No appreciable evidence of apoptosis could be detected on either day 3 or day 5 of serum withdrawal in cells carrying the vector minus the IGF-IR inserts (Fig 5, lanes 1 and 2, respectively) .
The induction of DNA fragmentation was also confirmed using a TUNEL assay. TUNEL is a sensitive and quantitative method for the detection of 3Ј-OH ends generated by endonuclease-mediated DNA strand breaks.
29 Figure 6 shows a flow cytometric analysis of cells from the C9 clone carrying antisense IGF-IR. There is a peak on the histogram (Fig 6A, right panel) that indicates that ϳ59% of the cells from the C9 clone carrying antisense IGF-IR are apoptotic. Conversely, the MDA-MB-435s cells carrying the construct minus the antisense IGF-IR insert (Fig 6B, right panel) display a peak similar to the negative control (Fig 6B, left panel) , indicating that there is no evidence of apoptosis in these cells.
To assess whether treatment of the MDA-MB-435s human breast cancer cells with antisense IGF-IR affects the tumorigenic potential of the cells in vivo, assays were carried out in female athymic mice. The mice were injected with cells from the antisense IGF-IR C8 or C9 clones or with control cells carrying the construct minus the IGF-IR inserts. A dramatic inhibition in tumorigenesis was observed in the mice injected with cells from either the C8 or C9 clone (Fig 7, A and B, respectively) . Conversely, the animals injected with cells carrying the construct minus the antisense IGF-IR insert developed large tumors (Fig 7C) . Figure 8 shows that the nude mice injected with cells from the C8 or C9 clone displayed a significant delay in the onset of tumor formation and a marked inhibition in tumor size compared with tumors from mice injected with cells carrying the construct minus the IGF-IR inserts. Three of four mice injected with cells from the C8 clone remained tumor free at the end of 11 weeks. All mice injected with cells from the C9 clone developed tumors; however, the tumors were significantly smaller than the tumors that formed after injection of control cells.
To establish whether the rudimentary immune system that exists in nude mice (deficient in T cells) plays a role in the development of tumors, a bioassay using nude and scid beige mice (deficient in T, B, and natural killer cells) was carried out. All of the mice that were injected with the MDA-MB-435s cells carrying the construct minus the IGF-IR inserts developed tumors. This is most likely due to the fact that the scapular region into which the cells were injected houses the first and second thoracic subcutaneous mammary fat pads in the mouse and therefore provides an orthotopic site for growth of the breast cancer cells. 30 The tumor size was dramatically reduced in all animals injected with cells from the C8 (Fig 9, u) or C9 (Fig 9, Ⅺ) clones when compared with mice injected with MDA-MB-435s cells transfected with the control vector (Fig 9, f) . Animals injected with cells from the C8 or C9 antisense IGF-IR-expressing clones showed significantly reduced tumorigenicity with no apparent metastases to the lungs (Table 2 ). However, in animals injected with the cells carrying the construct minus the antisense IGF-IR insert, only the scid beige mice had metastases to the lungs at the time of sacrifice (Table 2 ). This finding suggests that the rudimentary immune system plays a role in suppressing metastases in nude mice and indicates that the scid beige mouse model may be the most suitable model for studying the metastatic potential of these human breast cancer cells.
An additional bioassay using scid beige mice was performed to investigate the long-term effects on tumorigenesis after treatment of MDA-MB-435s cells with an antisense IGF-IR approach. The survival curve shows that cells from both the C8 (Fig 10, dashed line) and C9 (Fig 10, dotted line) clones carrying antisense IGF-IR resulted in a significantly prolonged survival for the animal. Conversely, all of the animals injected with cells carrying the construct minus the antisense IGF-IR insert (Fig 10, solid line) died or needed to be sacrificed within 4 months of receiving the cells. Overall, the animals injected with cells from the C9 clone showed the greatest increase in survival. The animals injected with cells from the C8 clone also had a significant increase in survival, but this increase was not as dramatic as the increase observed for the animals injected with cells from the C9 clone. The increased survival appears to correlate with the level of antisense IGF-IR expression and the degree of suppression of endogenous IGF-IR, as shown in Figure 2 . 4 and 6, respectively) . There was no apparent laddering in the cells carrying the vector minus the IGF-IR inserts on either day 3 or day 5 (lanes 1 and 2, respectively). Cells were harvested, and the DNA was extracted, labeled, and electrophoresed as described in Materials and Methods. This result was reproduced in four experiments. The molecular marker DNA, cleaved with EcoRI and HindIII ladder on the left, was used to determine size in base pairs.
DISCUSSION
Our data provide support for the functional role of the IGF-IR in the tumorigenesis and metastasis of MDA-MB-435s human breast cancer cells. We used an antisense gene therapy strategy that targets the IGF-IR to define the mechanisms that are involved in the growth and progression of this metastatic estrogen receptornegative human breast cancer cell line. Studies have reported that there is a highly significant correlation between a high IGF-IR expression and better prognosis. 31, 32 However, several small series studies showed an association with a shorter disease-free survival when the tumors were estrogen receptor-negative and IGF-IRpositive; in addition, these studies indicated that high IGF-IR levels correlated with resistance to radiotherapy. 33, 34 The MDA-MB-435s human breast cancer cell line was used in these studies because loss of the estrogen receptor often indicates a poorer prognosis for the patient. 35 We carried out a series of experiments to determine whether down-regulation of IGF-IR by an antisense approach could change the phenotype of these metastatic human breast cancer cells.
We extended the findings of others that showed that targeting the IGF-IR by both monoclonal antibodies directed against IGF-IR and antisense strategies inhibits breast cancer cell growth in vitro. The monoclonal antibody ␣IR3 has been used to block the IGF-IR and successfully inhibit the growth of estrogen receptornegative MDA-MB-231 human breast cancer cells. 36 An antisense strategy directed against IGF-IR has been used to suppress IGF-IR expression in MCF-7 human breast cancer cells. 21 The current data show that the IGF-IR is a require- ment for the growth of MDA-MB-435s human breast cancer cells. In this study, we reported that MDA-MB435s human breast cancer cells carrying an antisense IGF-IR construct exhibited a decrease in expression of IGF-IR at the mRNA level. The reduction in the expression of endogenous IGF-IR correlated with the inhibition in the cell proliferation rate, with cells from the C9 clone displaying the greatest decrease in cell proliferation rate; cells from the C8 clone had a slightly higher proliferation rate than cells from the C9 clone. Similar results have been demonstrated for other cancer cell types, including human ovarian carcinoma cells and human glioblastoma cells (T98G cells). 37, 38 The abolishment of anchorage-independent growth in soft agar by cells from the C8 and C9 clones suggests that the transformed phenotype has been reversed after treatment with antisense IGF-IR. Several studies have reported that the reduction of IGF-IR expression with antisense RNA correlates with a reversal of the transformed phenotype in tumor cells. 13, 37, 38 We found that the antisense strategy was more effective in inhibiting the growth of MDA-MB-435s cells in soft agar than in the cell proliferation assay. This is in agreement with a report that showed that the IGF-IR has a more profound influence on the transformed phenotype than on cellular proliferation for several tumor cell lines, including MCF-7 human breast cancer cells. 39 It is interesting to note that the abrogation of colony formation in soft agar does not always translate to a complete inhibition of tumorigenesis in vivo. This could be due to the length of time the cells are studied, because in vivo experiments are carried out over a period of several weeks or months; in contrast, in vitro experiments are usually assessed after several days or a few weeks. Indeed, it has been shown that tumors that arose from antisense IGF-IRtransfected rat glioblastoma cells and human melanoma cells had lost the IGF-IR antisense expression plasmid. 12, 13 The IGF-IR has been reported to be an important factor in the regulation of apoptosis in mammalian cells. A decrease in the number of receptors causes massive apoptosis, whereas overexpressed IGF-IRs protect cells from apoptosis. 28 We have demonstrated that the breast cancer cells treated with the antisense IGF-IR construct displayed apoptosis in vitro under serum withdrawal conditions. Cells from both the C8 and C9 clones carrying antisense IGF-IR were apoptotic by DNA laddering. In addition, cells from the C9 clone showed extensive apoptosis by flow cytometric analysis that correlated with the decreased cell proliferation rate and with the reduced expression of endogenous IGF-IR. It has been suggested that a reduction in the number of IGF-IRs is the functional equivalent of a withdrawal of growth factors. 28 It is possible that cells carrying antisense IGF-IR have an increased sensitivity to serum withdrawal and therefore are more likely to undergo apoptosis than cells carrying the control vector. In this study, we did not ask whether the in vivo apoptotic response after down-regulation of IGF-IR would be greater than that observed under our in vitro culture conditions. However, it has been reported that cells from both human and rodent tumors that were transfected with a stable antisense IGF-IR plasmid displayed massive apoptosis under in vivo conditions within 24 hours after being placed in a biodiffusion chamber that was inserted into the subcutaneous tissue of nude mice or syngeneic animals. 28, 40 We have also demonstrated that there was a significant delay in tumor formation and a dramatic reduction in tumor size when cells from the C8 and C9 clones carrying antisense IGF-IR were injected into the region of the mammary fat pad in nude mice. Indeed, there were several animals injected with cells from the C8 clone that were tumor free at the time of sacrifice. We have reported previously that rat prostate cancer cells treated with a construct carrying antisense IGF-IR have a delay in the formation of tumors and significant inhibition of tumor growth in nude mice. 19 Furthermore, we demonstrated in a recent study that treatment of rat C6 glioblastoma cells with a transfection vector that was constructed to drive transcription of the homopurine (AG) sequence 3Ј to the termination codon of the IGF-IR that can form a potential triple helix resulted in a dramatic inhibition of tumor growth in vivo. 20 In addition the down-regulation of IGF-IR by either antisense or a potential triple helix approach resulted in up-regulation of the cell surface expression of major histocompatibility complex I, suggesting that there may be an immune system component involved in the suppression of tumorigenesis. 20 Indeed a study by Resnicoff et al 13 demonstrated that the injection of C6 cells expressing antisense IGF-IR RNA into syngeneic animals provided protection against tumor induction by C6 wild-type cells and in fact caused complete regression of established C6 wild-type tumors. Therefore, the mechanisms by which gene therapy strategies targeting IGF-IR inhibit the growth of some tumor cells may be through a decrease in receptor number as well as by as yet undefined immune components. We observed that although tumors formed in the mice injected with cells carrying antisense IGF-IR from the C8 and C9 clones, there were no apparent metastases to the lungs after 11 weeks. Our results are in agreement with a report that demonstrated that cells from a highly metastatic murine hepatic carcinoma lost their metastatic phenotype when transfected with a plasmid vector expressing IGF-IR cDNA in the antisense orientation. 41 These investigators suggested that in cells expressing IGF-IR antisense RNA, the growth advantage in the liver and lung is apparently lost. However, the results from our bioassay comparing tumor formation and metastases in nude mice with that in scid beige mice raise some interesting questions about the role of the rudimentary immune system present in nude mice on the metastatic progression of cancer cells. We found that all of the scid beige mice injected with MDA-MB-435s cells carrying the construct minus the antisense IGF-IR insert had metastases to the lungs after 11 weeks, whereas there were no detectable lung metastases in the nude mice. This suggests that the rudimentary immune system present in nude mice played an important role in inhibiting the development of metastasis from the MDA-MB-435s breast cancer cells. Previous studies have reported that scid mice that lack functional T and B cells are better models for human tumor transplantation than nude mice. 42, 43 These investigators demonstrated that the nude mouse displays a residual systemic immunoreactivity that is significantly higher than that of the scid mouse. Our data indicate that the scid beige mouse may be a more suitable animal model for studying metastatic progression in the MDA-MB-435s human breast cancer cells. We also showed that scid beige mice injected with cells from the C8 and C9 clones carrying antisense IGF-IR had a dramatically prolonged survival compared with animals injected with cells carrying the control construct. This finding indicates that IGF-IR plays an important role in the growth and progression of this human breast cancer cell line. Whether this will be the case for other types of breast cancer cells remains to be determined.
In conclusion, our data demonstrate that the IGF-IR plays a pivotal role in proliferation, transformation, tumorigenesis, and growth progression in a metastatic estrogen receptor-negative human breast cancer cell line. Moreover, we have provided evidence that indicates the importance of establishing and using the optimal animal model for studying the effects of downregulation of IGF-IR by antisense strategies under in vivo conditions. New approaches targeting the IGF-IR may provide an effective antimetastatic treatment strategy for patients that have progressive estrogen receptornegative breast cancer. 
